Nieuwscentrum

okt 28, 2019

Philips maakt cijfers derde kwartaal 2019 bekend


Philips behaalt in het derde kwartaal een omzet van EUR 4,7 miljard, met een groei van de vergelijkbare omzet van 6%, een resultaat uit doorlopende activiteiten van EUR 211 miljoen en een gecorrigeerde EBITA-marge van 12,4%

Kerncijfers derde kwartaal

  • De omzet in het kwartaal bedroeg EUR 4,7 miljard, met een groei van de vergelijkbare omzet van 6%
  • De vergelijkbare orderontvangst was in lijn met Q3 2018
  • Het resultaat uit doorlopende activiteiten bedroeg EUR 211 miljoen, inclusief een last van EUR 78 miljoen in verband met goodwillafboeking, vergeleken met EUR 307 miljoen in Q3 2018
  • De gecorrigeerde EBITA-marge was 12,4% van de omzet, vergeleken met 13,2% van de omzet in het derde kwartaal van 2018
  • Het bedrijfsresultaat nam toe naar EUR 320 miljoen, vergeleken met 451 miljoen in Q3 2018
  • De WPA uit doorlopende activiteiten (verwaterd) bedroeg EUR 0,23; de bijgestelde WPA uit doorlopende activiteiten (verwaterd) steeg met 10% in vergelijking met het derde kwartaal van 2018 tot EUR 0,46
  • De operationele kasstroom steeg naar EUR 356 miljoen, vergeleken met EUR 265 miljoen in het derde kwartaal van 2018; de vrije kasstroom steeg naar EUR 126 miljoen, vergeleken met EUR 52 miljoen in het derde kwartaal van 2018

 

Frans van Houten, CEO

 

“Het derde kwartaal heeft gemengde resultaten opgeleverd voor de Groep. We noteerden een sterke groei van de vergelijkbare omzet van 6%, gedreven door de innovatieve producten en oplossingen in al onze activiteiten. Dit werd weerspiegeld in de midden-eencijferige groei van de vergelijkbare omzet in gevestigde regio’s en de hoge ééncijferige groei in groeiregio's, met een dubbelcijferige groei in China.

 

De vergelijkbare orderontvangst bleef stabiel, na een sterke groei van 11% in het derde kwartaal van 2018, als gevolg van de ongelijke dynamiek van de orderontvangst en zwakte in Noord-Amerika. Over de laatste 12 maanden nam de vergelijkbare orderontvangst toe met 5%.

 

De gecorrigeerde EBITA-marge in de Diagnosis & Treatment en Personal Health activiteiten vertoonde een aanhoudende verbetering. Zoals we echter al aankondigden in onze update op 10 oktober 2019, daalde de gecorrigeerde IBITA-marge in de Connected Care activiteiten naar 11,3% als gevolg van de toenemende tegenwind door invoerrechten en een vertraging in de impact van de mitigerende stappen, een te geringe dekking in de fabriek en een negatief effect van de productmix. De gecorrigeerde EBITA voor de Groep werd ook beïnvloed door lagere inkomsten uit licenties in het segment Overig.

 

Over het gehele jaar 2019 verwachten we dat de groei binnen de bandbreedte van 4-6% zal blijven. We verwachten dat de gecorrigeerde EBITA-marge zal verbeteren met circa 10 tot 20 basispunten gezien de in het algemeen aanzienlijke tegenwind en het prestatietraject van de Connected Care activiteiten, die we momenteel aanpakken. Voor 2020 verwachten we 4-6% groei in vergelijkbare omzet en een verbetering van de gecorrigeerde EBITA-marge van gemiddeld 100 basispunten.”

Reporting segment performance

 

The Diagnosis & Treatment businesses recorded 9% comparable sales growth, with double-digit growth in Ultrasound and high-single-digit growth in Diagnostic Imaging and Image-Guided Therapy. Comparable order intake was in line with Q3 2018. The Adjusted EBITA margin increased 2.1 percentage points to 14.0%, driven by sales growth and productivity, partly offset by the impact of tariffs.

 

Comparable sales in the Connected Care businesses increased 5%, with mid-single-digit growth in Monitoring & Analytics and Sleep & Respiratory Care. Comparable order intake was in line with Q3 2018. The Adjusted EBITA margin decreased 4.5 percentage points to 11.3%, as outlined above.

 

The Personal Health businesses delivered comparable sales growth of 6%, with double-digit growth in Oral Healthcare and high-single-digit growth in Domestic Appliances. The Adjusted EBITA margin increased 0.3 percentage points to 14.7%, mainly due to sales growth, partly offset by investments and the impact of tariffs.

 

Philips’ ongoing focus on innovation and strategic partnerships resulted in the following highlights in the quarter:

 

  • Philips Reinforcing its global leadership in image-guided therapy, Philips launched its highly successful Azurion platform in China, following clearance from the National Medical Products Administration. Moreover, in the US, Philips launched the longer 150 mm and 200 mm versions of its Stellarex low-dose drug-coated balloons to broaden treatment options for peripheral artery disease patients.
  • Philips’ app-based, mobile Lumify ultrasound solution delivered double-digit comparable sales and order intake growth, as it continues to set the industry standard by consistently delivering what customers need to provide the best care for their patients at the point of care – diagnostic clarity, reliability and continuous scanning, with a lightweight, replaceable transducer.
  • Philips introduced an industry-first ‘Tube for Life’ guarantee on its new Incisive CT imaging platform in North America following its successful introduction in Europe and Asia. The new CT platform integrates innovations in imaging, workflow, and lifecycle management, helping healthcare providers with smart clinical decision-making, increased efficiency and improved experience for patients and staff.
  • Philips further expanded its Enterprise Diagnostic Informatics portfolio with the completion of the acquisition of Carestream Health’s Healthcare Information Systems business. Adding a state-of-the-art cloud-based imaging data platform, Philips’ offering now includes advanced Vendor Neutral Archive solutions, diagnostic and enterprise viewers, interactive multimedia reporting, AI-enabled clinical, operational and business analytics tools, as well as tele-radiology and diagnostic patient management services.
  • Reinforcing its leadership in patient monitoring solutions, Philips introduced the next-generation IntelliVue MX750 and MX850 bedside patient monitor platforms in Europe. These feature an extensive range of measurements and analytics, as well as new cybersecurity capabilities. Moreover, Philips signed multi-year enterprise patient monitoring agreements with the Kantonsspital Frauenfeld (Switzerland) and the University Clinic of Bonn (Germany) to improve workflow and clinical outcomes in these hospitals.
  • Philips teamed up with Walgreens, one of the largest drugstore chains in the US, to integrate the clinically validated Philips SmartSleep Analyzer with the Walgreens Find Care platform, which helps connect Walgreens’ millions of mobile and online visitors to healthcare services. Walgreens Find Care users are now able to use Philips’ tool to help identify the potential reasons contributing to their sleep issues and connect to sleep diagnostics, guidance, products and solutions.
  • Further broadening its product range in oral care, Philips has rolled out its connected Philips Sonicare ExpertClean globally. The new smart power toothbrush delivers superior oral care results with its sonic technology and deep clean brushing mode.

 

Cost savings

 

In the third quarter of 2019, cost savings totaled EUR 96 million, reflecting procurement savings of EUR 41 million and savings from overhead and other productivity programs of EUR 55 million.

 

Capital allocation

 

As of the end of the third quarter of 2019, Philips has completed 32.9% of its EUR 1.5 billion share buyback program for capital reduction purposes that was announced on January 29, 2019. Further details can be found here

 

In the quarter, Philips sold all of its remaining shares in Signify (14.3%) for total proceeds of EUR 477 million.

 

Regulatory update

 

Philips continues to address the follow-up requests of the US Food and Drug Administration (FDA) as part of its efforts to fulfill its obligations under the Consent Decree [1] and remains in dialogue with the agency.

 

 

[1] Under the Consent Decree, Philips continues to export its complete range of AED devices and manufacture and distribute its H1/OnSite/Home automated external defibrillator (AED) model in the US. The company may also continue to service the AEDs provided that certain conditions are met and provide consumables and the relevant accessories.

Quarterly Report

Third Quarter Results 2019 - Quarterly Report

Presentation

Third Quarter Results 2019 - Quarterly Results Presentation

Conference call and audio webcast

A conference call with Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, to discuss the results will start at 10:00AM CET, October 28, 2019. A live audio webcast of the conference call will be available through the link below.

Q3 2019 – Third quarter 2019 results conference call audio webcast

 

More information about Frans van Houten and Abhijit Bhattacharya

 

Click here for Mr. van Houten's CV and images

Click here for Mr. Bhattacharya's CV and images


Visit our interactive results hub for more on our financial and sustainability performance over the past quarter, including the latest version of our dynamic Lives Improved world map.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Meer informatieMinder informatie

Forward-looking statements and other important information

 

Forward-looking statements


This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include: statements made about the strategy; estimates of sales growth; future Adjusted EBITA; future restructuring, acquisition-related and other costs; future developments in Philips’ organic business; and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

 

These factors include but are not limited to: global economic and business conditions; political instability, including developments within the European Union such as Brexit, with adverse impact on financial markets; the successful implementation of Philips’ strategy and the ability to realize the benefits of this strategy; the ability to develop and market new products; changes in legislation; legal claims and proceedings; increased healthcare regulation; changes in currency exchange rates and interest rates; changes in foreign currency import or export controls; future changes in tax rates and regulations, including trade tariffs; pension costs and actuarial assumptions; changes in raw materials prices; changes in employee costs; the ability to identify and successfully complete acquisitions, and to integrate those acquisitions into the business, the ability to successfully exit certain businesses or restructure the operations; the rate of technological changes; cyber-attacks, breaches of cybersecurity; political, economic and other developments in countries where Philips operates and industry consolidation and competition. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see the Risk management chapter included in the Annual Report 2018.

 

Third-party market share data

 

Statements regarding market share, including those regarding Philips’ competitive position, contained in this document are based on outside sources such as research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, those statements may also be based on estimates and projections prepared by outside sources or management. Rankings are based on sales unless otherwise stated.

 

Use of non-IFRS information

 

In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2018.

 

Use of fair value information

 

In presenting the Philips Group’s financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2018. In certain cases independent valuations are obtained to support management’s determination of fair values.

 

Presentation

 

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2018, except for IFRS 16 lease accounting, which is implemented per January 1, 2019.

 

As announced on January 10, 2019, Philips has realigned the composition of its reporting segments effective as of January 1, 2019. The most notable changes are the shifts of the Sleep & Respiratory Care business from the Personal Health segment to the renamed Connected Care segment and most of the Healthcare Informatics business from the renamed Connected Care segment to the Diagnosis & Treatment segment. Accordingly, the comparative figures have been restated. The restatement has been published on the Philips Investor Relations website and can be accessed here.

 

Market Abuse Regulation

 

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Meer informatieMinder informatie

Onderwerpen

Contact

Ben Zwirs

Ben Zwirs

Philips Global Press Office

Tel: +31 6 1521 3446

Martijn van der Starre

Martijn van der Starre

Philips Global Press Office

Tel: +31 6 2847 4617

Business Highlights Q3 2019

Business Highlight: Philips Incisive CT platform with industry-first ‘Tube for Life’ guarantee now available in North America
Philips Incisive CT platform with industry-first ‘Tube for Life’ guarantee now available in North America.
Business Highlight - Philips’ intelligent health solutions at IFA 2019 adapt to individual consumer needs.
Philips’ intelligent health solutions adapt to individual consumer needs.
Business Highlights - IntelliVue MX850
Reinforcing its leadership in patient monitoring solutions, Philips introduced the next-generation IntelliVue MX750 and MX850 bedside patient monitor platforms in Europe.

Deel op social media